Precigen - PGEN Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PGEN shares.
View PGEN analyst ratings or view top-rated stocks.

3 brokers have issued 12 month price targets for Precigen's stock. Their PGEN share price forecasts range from $6.00 to $14.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 394.5% from the stock's current price.
View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts.

Precigen's stock was trading at $3.71 at the beginning of the year. Since then, PGEN shares have decreased by 50.9% and is now trading at $1.82.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our PGEN earnings forecast.

Precigen, Inc. (NASDAQ:PGEN) issued its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The biotechnology company had revenue of $21.56 million for the quarter, compared to analysts' expectations of $24.47 million. Precigen had a net margin of 33.55% and a negative trailing twelve-month return on equity of 82.23%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).

Precigen trades on the NASDAQ under the ticker symbol "PGEN."

Precigen's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.76%), Vanguard Group Inc. (2.44%), Iridian Asset Management LLC CT (1.54%), State Street Corp (0.93%), Renaissance Technologies LLC (0.40%) and Nuveen Asset Management LLC (0.29%). Insiders that own company stock include David M Obstler, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rick L Sterling, Thomas Bostick and Trading SA Ares.
View institutional ownership trends.

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PGEN stock can currently be purchased for approximately $1.82.

Precigen (NASDAQ:PGEN) has a market capitalization of $378.83 million and generates $103.87 million in revenue each year. The biotechnology company earns $-92,170,000.00 in net income (profit) each year or $0.12 on an earnings per share basis.

The company employs 456 workers across the globe.

Precigen's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The official website for the company is www.precigen.com. The biotechnology company can be reached via phone at (301) 556-9900 or via email at investors@precigen.com.